[{"id":"05e2894e-1d38-44e0-96cc-d79414cd4c88","acronym":"V941-001","url":"https://clinicaltrials.gov/study/NCT03948763","created_at":"2021-01-18T19:26:20.412Z","updated_at":"2024-07-02T16:36:04.359Z","phase":"Phase 1","brief_title":"A Study of mRNA-5671/V941 as Monotherapy and in Combination With Pembrolizumab (V941-001)","source_id_and_acronym":"NCT03948763 - V941-001","lead_sponsor":"Merck Sharp \u0026 Dohme LLC","biomarkers":" EGFR • KRAS • ALK • MSI","pipe":" | ","alterations":" KRAS mutation • EGFR mutation • EGFR positive • HLA-A*11","tags":["EGFR • KRAS • ALK • MSI"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e KRAS mutation • EGFR mutation • EGFR positive • HLA-A*11"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Keytruda (pembrolizumab) • mRNA-5671"],"overall_status":"Completed","enrollment":" Enrollment 70","initiation":"Initiation: 06/26/2019","start_date":" 06/26/2019","primary_txt":" Primary completion: 08/25/2022","primary_completion_date":" 08/25/2022","study_txt":" Completion: 08/25/2022","study_completion_date":" 08/25/2022","last_update_posted":"2022-09-07"}]